Cholera diagnosis in human stool and detection in water: A systematic review and meta-analysis

Jennifer Falconer, Karin Diaconu, Fiona O'May, Advaith Gummaraju, Ifeyinwa Victor-Uadiale, Joseph Matragrano, Berthe-Marie Njanpop-Lafourcade, Alastair Ager

1 Institute for Global Health and Development, Queen Margaret University, Edinburgh, Scotland, 2 London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Columbia University, New York, New York, United States of America, 4 Agence de Médecine Préventive, Paris, France, 5 Mailman School of Public Health, Columbia University, New York, New York, United States of America

* jennifer@falconers.me.uk

Abstract

Background
Cholera continues to pose a problem for low-resource, fragile and humanitarian contexts. Evidence suggests that 2.86 million cholera cases and 95,000 deaths due to cholera are reported annually. Without quick and effective diagnosis and treatment, case-fatality may be 50%. In line with the priorities of the Global Task Force on Cholera Control, we undertook a systematic review and meta-analysis of diagnostic test accuracy and other test characteristics of current tests for cholera detection in stool and water.

Methods
We searched 11 bibliographic and grey literature databases. Data was extracted on test sensitivity, specificity and other product information. Meta-analyses of sensitivity and specificity were conducted for tests reported in three or more studies. Where fewer studies reported a test, estimates were summarised through narrative synthesis. Risk of Bias was assessed using QUADAS-2.

Results
Searches identified 6,637 records; 41 studies reporting on 28 tests were included. Twenty-two tests had both sensitivities and specificities reported above 95% by at least one study, but there was, overall, wide variation in reported diagnostic accuracy across studies. For the three tests where meta-analyses were possible the highest sensitivity meta-estimate was found in the Cholera Screen test (98.6%, CI: 94.7%-99.7%) and the highest specificity meta-estimate in the Crystal VC on enriched samples (98.3%, CI: 92.8%-99.6%). There was a general lack of evidence regarding field use of tests, but where presented this indicated trends for lower diagnostic accuracy in field settings, with lesser-trained staff, and without the additional process of sample enrichment. Where reported, mean test turnaround
times ranged from over 50% to 130% longer than manufacturer’s specification. Most studies had a low to unclear risk of bias.

Conclusions
Currently available Rapid Diagnostic Tests can potentially provide high diagnostic and detection capability for cholera. However, stronger evidence is required regarding the conditions required to secure these levels of accuracy in field use, particularly in low-resource settings.

Registration
PROSPERO (CRD42016048428).

Introduction
Cholera is caused by the etiological agents *Vibrio cholerae* O1 and O139 serogroups and transmitted through the faecal-oral route by consuming contaminated food or water [1, 2]. The predominant symptom is acute watery diarrhoea, which may be like rice-water, and sometimes accompanied by vomiting; although only 20% of those infected develop these symptoms. Without treatment with oral and intravenous rehydration therapy, case fatality may be as high as 50% [3].

While recent estimates are not available, earlier evidence suggests that in endemic countries, cholera is responsible for an estimated 2.86 million cases, and 95,000 deaths annually, with 1.3 billion people at risk [4]. Figures are likely to be an underestimate given inadequate surveillance systems, diagnostic tests, and a reluctance by authorities to acknowledge outbreaks [5]. The heaviest burden occurs in sub-Saharan Africa and South Asia, but the disease is endemic in Africa, Asia, South America, and Central America [4, 6]. Epidemics occur frequently in fragile and conflict-affected states, where the logistical coordination of intervention delivery is complex. In the past ten years large outbreaks have been seen in countries including Yemen, Haiti, Iraq, Sierra Leone, Somalia, South Sudan, Tanzania, and Zimbabwe [7, 8]. The Yemen outbreak between April 2017 and October 2018 was the largest ever epidemiologically seen, with over 1.2 million cases reported, of which 2,556 cases proved fatal [9].

Diagnosis and detection in the early stages of an epidemic are essential for outbreak confirmation and control, and identification of areas for targeted interventions to control disease spread [5, 10]. Bacterial culture continues to be considered the gold standard for diagnosis of cholera—from both water or stool samples, yet suffers from issues surrounding precision, sample transport, laboratory infrastructure, a time delay of two to three days, and necessity of highly trained laboratory technicians [1, 10]. Use of polymerase chain reaction (PCR) to detect cholera is becoming increasingly common, yet, like culture, requires a laboratory and highly trained staff, both of which are sparsely available in the settings in which cholera outbreaks are most common [10, 11].

The Global Task Force on Cholera Control highlights early identification as critical to cholera detection [12] and Rapid Diagnostic Tests (RDTs) are widely viewed as a pragmatic alternative to laboratory-based detection methods [5]. For humanitarian response, detection in both water samples and stool is particularly promising [12].
RDTs potentially provide a cheap, accurate, quick, easy to use, and robust diagnostic tool [10, 11]. Over the past three decades a number of such tests have been developed and validated—e.g., Crystal VC, and the Institut Pasteur (IP) dipstick—in field settings including Bangladesh, Guatemala, Mexico, and Mozambique [11]. A previous review on the topic carried out in 2012 by Dick et al. [11] identified 24 cholera diagnostic tests, including RDTs, PCR technologies, agglutination, and direct fluorescence antibodies. Turnaround time of these tests was as little as 15 minutes. However, diagnostic accuracy of these RDTs for individual patients was variable; reported sensitivities ranged from 58–100%, and specificities from 60–100%. Additionally, the quality of the 18 peer-reviewed articles included in the review was found to be low, with issues surrounding sample size and sample types, the context of field-tests, and gold standards [11]. More recently, two reviews of methods for detecting cholera have been published [13, 14]. These both cover laboratory tests and field-based RDTs and focus on the technical mechanisms by which these different tests work. Ramamurthy and colleagues [13] particularly highlight new methods such as loop-mediated isothermal amplification (LAMP) with the use of a lateral chromatographic flow dipstick and use of genome sequencing data, which show promising results for detection of cholera—however research on these in field settings is currently limited.

While these three reviews provide a scope of the field of cholera diagnostic tests, they are not systematic reviews, and did not review the literature using rigorous search methods, nor do they undertake any meta-analysis. Finally, critical information on product design, pricing, ease of use and training requirements were missing from these reviews—this information is highly pertinent given the low-resource settings in which these products are most needed.

Evidence surrounding accurate cholera diagnosis, and in particular rapid diagnostic tests, remains highly topical, with recent reviews suggesting that such tests still see limited use for either surveillance or outcome detection [15]. This study aimed to appraise the evidence of diagnostic accuracy and other features relevant to use in low-income settings (such as pricing and design features) of current cholera diagnosis and detection tests for use with water or stool samples. This analysis is clearly relevant in the assessment of the suitability of current diagnostic tests for the wider use in such settings required to meet roadmap goals. Further, noting the emergence of novel diagnostic technologies [16, 17], it is also relevant in informing the target product profile required of any new product proposed for use at scale in low-resource contexts in this field.

Methods

A systematic review and meta-analysis were undertaken to identify current products for cholera diagnosis or detection in stool or water samples. The review was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis of Diagnostic Test Accuracy (PRISMA-DTA) guidelines [18]. A completed PRISMA-DTA checklist is available in S1 Appendix.

A protocol for this study was published in 2018 [16] and the review is registered with PROSPERO (CRD42016048428).

Search strategy and study selection

Eleven databases, comprising both peer-reviewed and grey literature, were searched: MEDLINE, Embase, CINAHL, Scopus, ProQuest, Global Health Library (WHOLIS), IndMed, OpenGrey, WHO IRIS, ClinicalTrials.gov, and ICTRP WHO. A full list of search strategies can be found in S2 Appendix. Initial searches were carried out in October 2017 and updated in March 2020. Reference lists of included studies were scanned for additional relevant records.
Searches were undertaken by one reviewer (JF) and screened by two reviewers (JF and KD). Discrepancies were resolved through discussion, and by an arbiter (JM) where no consensus could be reached.

**Inclusion and exclusion criteria**

Study inclusion was determined according to the following criteria:

- **Population.** People suspected to be infected with cholera.
- **Index test.** Diagnostic tests developed for rapid use with field samples.
- **Target condition.** Detection of *V. cholerae* in human stool and water.
- **Reference test.** Culture or PCR, or a combination reference including one of these.
- **Setting.** Field or laboratory setting.
- **Outcome.** Sensitivity and specificity.

We included primary field and laboratory evaluations of any study design that compared a test for cholera to a reference test, validated using field samples of water or human stool. We excluded studies which used only artificially created cholera samples and studies without a non-cholera control—i.e., that only included samples positive for cholera. We also excluded abstracts and articles with insufficient information on our review objective, non-research reports, opinions, editorials, and modelling studies.

No restrictions were placed upon publication date, language, or location of study.

**Data extraction and analysis**

In line with the protocol, analysis of studies included descriptions of:

- Diagnostic accuracy of the products—e.g., sensitivity and specificity
- Technical characteristics of products—e.g., detection target and turnaround time
- Information on product pricing and ease of use

Positive and negative predictive values (PPV and NPV) were intended for inclusion as per the study protocol, however, due to inconsistencies in reporting PPV and NPV, we focussed solely on sensitivity and specificity.

Information was therefore extracted from papers on: study characteristics; product specifications of diagnosis and detection technologies; sample characteristics, preparation, and handling; outcome measures including sensitivity, specificity, true positives, false positives, true negatives, false negatives; and data on test pricing, design characteristics, and ease of use. Data extraction was performed in duplicate using an extraction sheet designed and piloted prior to study selection. One reviewer (JF) extracted all papers, with second extraction done by a team of three reviewers (KD, FO’M and AG). Discrepancies were resolved by an independent arbiter (IV).

Study quality and bias were assessed using the QUADAS-2 tool for studies of diagnostic accuracy [19]. Risk of bias was assessed by two reviewers (JF and KD). QUADAS-2 questions were focused on assessing both risk of bias and applicability and in the case of laboratory studies were adapted to include consideration of both patient and sample selection. Where no information was presented at all or insufficient information was available to reach judgment, we noted answers to QUADAS-2 as unclear. Where information was available, and studies used good practice in line with other studies of diagnostic accuracy, and concerns over test applicability were not present, we judged risk of bias and concerns over applicability as low.

To reach judgments on applicability, we considered all relevant test characteristics discussed in the document review—i.e., both issues of diagnostic accuracy, but also intended use of test as described by authors, including relevant information on technical specifications and cost of test among others. No formal assessment of publication bias was conducted.
**Meta-analysis.** Meta-analyses of sensitivity and specificity were undertaken according to the methods outlined in Shim et al., 2019 [20]. Meta-analyses were carried out where data was available for three or more studies testing on the same sample type (i.e., stool or water), with the same sample handling (i.e., direct versus enriched samples). Raw numbers of true positives, false positives, true negatives, and false negatives were required, so studies without this information were excluded from meta-analysis. A separate meta-analysis was carried out for each reference test where these criteria were met.

A random effects model was used to account for variation across studies, and forest plots were produced to provide a visual depiction of variability. To avoid sample overlap, only one estimate of sensitivity and one estimate of specificity was included per study in each meta-analysis. The one exception to this was where studies reported separate estimates by geographical location. Where studies had more than one estimate calculated based on the same samples (e.g., due to lab technicians and field technicians both undertaking the test), priority was given to results obtained from settings most similar to that intended by the test.

Due to the correlation of sensitivity and specificity estimates, additional analyses were undertaken to overcome this and provide single meta-estimates of diagnostic accuracy.

Summary receiver operating characteristic (SROC) curves of sensitivity against false positive rate (false positive rate = 1-specificity) were plotted and the area under the curve (AUC) calculated. The AUC varies from 0 to 1 and estimates the percentage of correct predictions of a test, with a value of 0 representing a test whose diagnoses are 100% wrong, 1 representing a test whose diagnoses are 100% correct, and 0.5 representing a test with a 50% chance of a correct diagnosis.

Additional supplementary meta-analyses were undertaken using diagnostic odds ratios (DOR). Further details can be found in S3 Appendix.

**Narrative synthesis.** Given meta-analysis was not possible for the majority of tests, sensitivity and specificity results were also synthesized narratively, by presenting a range of estimates for each test, and plotting sensitivities and specificities graphically. Tests were sorted into three groups for narrative synthesis: immunologically-based tests, PCR-based tests, and ‘other’ test types. Results of studies were sub-grouped by intended location of test, sample type, target, and whether the sample was enriched prior to testing. For each of these groups the range of sensitivities and specificities reported in studies is detailed. Tests were classified as laboratory evaluations or field evaluations according to a) the location where the test was undertaken and b) the personnel who undertook the test (for example field technicians or clinicians, versus lab technicians). This classification was undertaken by reviewers based on the descriptions of test procedures available in the included texts, and the assessment of this review may deviate from the ‘field’ or ‘laboratory’ label used by the authors of a study.

Information on other components of the diagnostic products was also synthesized narratively, within the same three groups. This means that where available we extracted and report on the information study authors provided regarding the way in which products are due to be used (including ease of use, necessary training of health care workers, instructions for use) and their potential value for money (e.g., elements of cost, efficiency of deployment).

Meta-analysis was undertaken in R version 3.6.3, and all other analysis was undertaken in Microsoft Excel.

**Results**

**Search results**

Searches identified 6,637 records. Once duplicates were removed, the titles and abstracts of 4,163 records were screened for relevance. Full text review was undertaken on 181 papers, and
35 were selected for analysis. The search process is detailed in Fig 1, including the reasons for exclusion of 146 records during the full text assessment.

During search updates in March 2020, a further 602 records were retrieved (after exclusion of duplicates with original search), and four additional studies identified for inclusion. Two further studies were identified through reference lists of included studies, resulting in 41 studies in total being included in the final analysis.

**Characteristics of included studies**

The 41 studies included 13 field assessments and 31 laboratory assessments of cholera diagnostic products (four studies included both field and laboratory assessments; one study was unclear on the location). Samples came from a range of countries, primarily in South and East Asia, the most reported being Bangladesh (13 studies) and India (eight studies). Twenty-eight different products were reported on. These included immunologically-based tests detecting lipopolysaccharides or proteins of *V. cholerae* (for example Crystal VC, Cholera SMART, and
Cholera Screen), and PCR-based tests detecting genes or nucleic acids (for example TaqMan Array Card). Most studies utilised stool samples in their testing, however five studies using water samples were included. Reference tests were overwhelmingly bacterial culture (in 33 studies), with PCR (in six studies), or combination references (three studies) also used. Overall, 24,835 samples were captured, with individual study sample sizes ranging from 27 to 6,497. Complete study characteristics are presented in Table 1.

The 28 different diagnostic tests and detection products reported included several different types of test. For the purposes of analysis, these were split into three broad categories, based on the mechanism of action of the diagnostic test: ‘immunologically-based’ tests detecting lipopolysaccharides or proteins, PCR-based tests, and ‘other tests’—which included selective media-based tests and real-time cell analysis. Immunologically-based tests are those detecting antigens of *V. cholerae* O1 and O139, such as lipopolysaccharides or proteins (reported in studies in a variety of ways, for instance ‘*V. cholerae* O1 antigen A’ [57], ‘*A* factor of *V. cholerae* O139’ [52], ‘*V. cholerae* O1 and O139 antigens’ [34]). These tests were predominantly intended for field use (17 of 20 tests). PCR-based tests are those detecting genes and nucleic acids associated with pathogenic *V. cholerae* through PCR, for instance detecting the toxR gene [44], or espM gene [46] of *V. cholerae*. Finally, other types of tests included selective media-based tests, and real-time cell analysis. In selective media-based tests, stool samples containing bacterial organisms—in this case *V. cholerae*—were grown on selective medium and preliminary identified on the basis of colony appearance [31]. The single cholera-toxin real-time cell analysis test included assesses how different mammalian cell types respond to cholera toxin as they grow [41].

**Results: Meta-analysis**

Three tests had sufficient data to undertake meta-analysis: Crystal VC, Cholera Screen, and IP dipstick. For Crystal VC separate meta-analyses were carried out for samples tested directly (“direct samples”) and samples enriched in Alkaline Peptone Water (APW) prior to testing (“enriched samples”); for IP dipstick, only direct samples could be included in the meta-analysis, as there was insufficient comparable data on enriched samples; for Cholera Screen all samples were tested directly.

Table 2 reports a summary of results obtained from the meta-analyses and the SROC analysis.

For tests on direct samples, Cholera Screen showed the highest sensitivity meta-estimate of the analysed tests, at 98.6% (95% CI: 94.7–99.7), with the lowest sensitivity meta-estimate reported in Crystal VC. Similarly, the latter test also had the lowest specificity meta-estimate, reported at 77.7% (CI 70.7–83.3), with the highest noted for the IP dipstick test.

Relating to tests used on enriched samples, only data from the Crystal VC is available. Considered alongside the other tests, the sensitivity meta-estimate is the lowest overall at 85.5% (68.1–94.4), however the specificity meta-estimate is highest overall at 98.3% (92.8–99.6).

Heterogeneity in sensitivity and specificity was seen across studies for each of the four meta-analyses, as can be seen from the ranges reported in Table 2. The highest variation was seen in the specificity of the Cholera Screen test, where the lowest reported specificity was 22.2% (6.4–47.6%) [25] and the highest 100.0% (93.3–100.0%) [39]. Forest plots providing a visual representation of the variation in sensitivity and specificity across tests and studies can be found in S3 Appendix.

The area under the curve estimates are high (greater than 0.8) across all tests, with the IP dipstick showing the highest AUC of 0.969. SROC curves plotting the sensitivity against false positive rate are reported in S3 Appendix.
Table 1. Characteristics of included studies.

| Study ID   | Country       | Index test(s)                                        | Intended test location | Location assessed by study | Reference standard(s)                          | Sample type | Sample size |
|------------|---------------|-----------------------------------------------------|------------------------|-----------------------------|-----------------------------------------------|-------------|-------------|
| Albert 1997 [21] | Not specified | PCR assay (with new primers O139-1 and O139-2)     | Laboratory             | Laboratory                  | Culture                                       | Stool       | 180         |
| Bhuiyan 2003 [22] | Bangladesh    | IP dipstick                                         | Field                  | Laboratory                  | Culture                                       | Stool       | 134         |
| Bolaños 2004 [23] | Costa Rica    | Cholera SMART                                       | Field                  | Laboratory                  | Culture                                       | Stool       | 283         |
| Bwire 2017 [24]  | Uganda        | Crystal VC                                          | Field                  | Laboratory                  | Culture                                       | Stool       | 102         |
| Carillo 1994 [25] | Peru          | Cholera Screen                                      | Field                  | Laboratory                  | Culture                                       | Stool       | 100         |
| Chaicumpa 1995 [26] | Thailand      | Dot-blot ELISA                                      | Laboratory             | Laboratory                  | Culture                                       | Stool       | 984         |
| Chaicumpa 1998 [27] | Thailand and India | Dot-blot ELISA                                       | Laboratory             | Laboratory                  | Culture                                       | Stool       | 6497        |
| Chakraborty 2013 [28] | Bangladesh    | Crystal VC                                          | Field                  | Laboratory                  | Culture                                       | Water       | 550         |
| Colwell 1992 [29]  | Guatemala      | Cholera Screen                                      | Field                  | Laboratory and Field        | Culture                                       | Stool       | 17          |
| Hasan 1994a [35]   | Bangladesh    | Cholera DFA                                         | Laboratory             | Laboratory                  | Culture                                       | Stool       | 44          |
| Hasán 1994b [36]   | Bangladesh    | Cholera SMART                                       | Field                  | Field                       | Culture                                       | Stool       | 44          |
| Hasán 1995 [37]    | India³        | BengalScreen                                        | Laboratory             | Laboratory                  | Culture                                       | Stool¹      | 35          |
| Hao 2017 [33]      | China         | Vch-UPT-LF                                          | Field                  | Laboratory                  | Combination (culture or 2+ of colloidal gold assay, real time fluorescent PCR, Vch-UPT-LF) | Water       | 102         |
| Harris 2009 [34]   | Guinea-Bissau | Crystal VC                                          | Field                  | Field                       | PCR                                           | Stool       | 101         |
| Islam 1994 [39]     | Bangladesh    | Cholera Screen                                      | Field                  | Laboratory                  | Culture                                       | Stool       | 57          |
| Islam 2019 [40]     | Bangladesh    | Crystal VC                                          | Field                  | Field                       | Culture                                       | Stool       | 5865        |

(Continued)
| Study ID | Country | Index test(s) | Intended test location | Location assessed by study | Reference standard(s) | Sample type | Sample size |
|---------|---------|---------------|------------------------|---------------------------|-----------------------|-------------|-------------|
| Jin 2013 [41] | China | CT-RTCA (cholera toxin real-time cell analysis) | Laboratory | Laboratory | Combination (two or more matching results among real-time PCR, VET-RPLA, and CT-RTCA results) | Stool | 100 |
| Kalluri 2006 [42] | Bangladesh | Cholera SMART | Field | Field and laboratory | Culture | Stool | 304 |
| | Bangladesh | IP dipstick | Field | Field and laboratory | Culture | Stool | 304 |
| | Bangladesh | Medicos dipstick | Field | Field and laboratory | Culture | Stool | 304 |
| Ley 2012 [43] | Zanzibar | Crystal VC | Field | Field and laboratory | Culture | Stool | 622 |
| Liu 2013 [44] | Laboratory in USA; clinical samples from Tanzania and Bangladesh | TaqMan Array Card (singleplex real time PCR format) | Laboratory | Laboratory | Conventional assay and PCR-Luminex | Stool | 189 |
| Matias 2017 [45] | Haiti | Crystal VC | Field | Laboratory | Culture | Stool | 511 |
| | Haiti | Artron RDT | Field | Laboratory | Culture | Stool | 129 |
| | Haiti | SD Bioline | Field | Laboratory | Culture | Stool | 451 |
| Montaz 2013 [46] | Iran | PCR (with primers specific to espM gene) | Laboratory | Laboratory | Culture | Water | 448 |
| Mukherjee 2010 [47] | India | Crystal VC | Field | Field | Culture | Stool | 212 |
| Mwaba 2018 [48] | Zambia | SD Bioline | Field | Field | Culture and PCR | Stool | 170 |
| Nato 2003 [49] | Madagascar | IP dipstick | Field | Laboratory | Culture | Stool | 140 |
| | Bangladesh | IP dipstick | Field | Laboratory | Culture | Stool | 102 |
| Ontweka 2016 [10] | South Sudan | Crystal VC | Field | Field | PCR | Stool | 101 |
| Page 2012 [50] | Democratic Republic of Congo | Crystal VC | Field | Field | Culture or Culture and PCR | Stool | 256 |
| Qadri 1994 [51] | Bangladesh | Co-agglutination test (COAT) | Field | Laboratory | Culture | Stool | 230 |
| Qadri 1995 [52] | Bangladesh | Bengal SMART | Field | Laboratory | Culture | Stool | 189 |
| Ramamurthy 1992 [53] | India | Bead ELISA | Laboratory | Laboratory | Culture | Stool | 75 |
| Ramamurthy 1993 [54] | India | Bead ELISA and PCR (with primers specific to V. cholerae O1) | Laboratory | Laboratory | Culture | Stool | 123 |
| Ramamurthy 1996 [55] | India | Bead ELISA | Laboratory | Laboratory | Culture | Stool | 95 |
| Rashid 2017 [1] | Bangladesh | Crystal VC | Unclear | Laboratory | Culture | Water | 1648 |
| Sayeed 2018 [56] | Bangladesh | cholkit | Field | Laboratory | Culture | Stool | 76 |
| | Bangladesh | Crystal VC | Field | Laboratory | Culture | Stool | 76 |
| | Bangladesh | Multiplex PCR (with: O139-rfb primers—O139F-2, O139R-2; O1-rfb primers—O1F-2, O1R-2; cholera toxin primers—VCT1, VCT2) | Laboratory | Laboratory | Culture | Stool | 76 |
| Supawat 1994 [57] | Thailand | Cholera diagnostic kit (mAb-based dot-blot ELISA) | Field | Field | Culture | Stool | 211 |

(Continued)
Results: Narrative synthesis of sensitivity and specificity

Given meta-analysis was not possible for the majority of tests, a narrative synthesis was also undertaken to capture diagnostic accuracy results. Tests were split into three categories: immunologically-based tests, PCR-based tests, and other test-types. We present the findings of the narrative analysis in the forthcoming section.

Table 3 presents a summary of findings of the diagnostic accuracy for each test. A full breakdown of the sensitivity and specificity results of individual studies can be found in S4 Appendix. Additionally, a full dataset of extracted and back-calculated values of sensitivity, specificity, true positives, false positives, true negatives and false negatives for each study can be found in S5 Appendix.

Immunologically-based tests detecting lipopolysaccharides or proteins. Twenty immunologically-based tests, with a total of 35 sub-groups, were included in the narrative synthesis.

Sensitivity. Of those tests intended for field use, the most frequently studied test—the Crystal VC—had reported sensitivities ranging from 65.6% (testing directly on stool samples with bacterial culture reference [1]) to 98.9% (on enriched stool samples with bacterial culture reference [24]). Several tests had reported sensitivity of 100% (nine tests, 12 sub-groups): the Cholera SMART, Cholera Screen, IP dipstick, two-tip dipstick ELISA, Vch-UPT-LF, Cholera

| Study ID   | Country    | Index test(s)                  | Intended test location | Location assessed by study | Reference standard(s) | Sample type | Sample size |
|-----------|------------|--------------------------------|------------------------|---------------------------|-----------------------|-------------|-------------|
| Tuteja 2007 [58] | India      | Two-tip dipstick sandwich ELISA | Unclear                | Unclear                   | Culture.             | Water       | 50          |
|           |            |                                |                        |                           |                       | Stool       | 75          |
| Wang 2006 [59] | Mozambique | IP dipstick                    | Field                  | Laboratory                | Culture              | Stool       | 391         |

1 Water also tested, but sensitivity and specificity data not available
2 For purposes of this review, ‘high probability samples’ were included in analysis
3 Results from Mexico excluded, due to absence of any cholera negative samples

https://doi.org/10.1371/journal.pone.0270860.t001

Table 2. Summary of results of meta-analyses.

| Test                        | No. Studies Included | Total Sample Size (Range) | Sensitivity (95% CI): range reported in included studies | Sensitivity Meta-estimate (95% CI) | Specificity (95% CI): range reported in included studies | Specificity Meta-estimate (95% CI) | Area Under Curve (AUC) estimate |
|-----------------------------|----------------------|---------------------------|-----------------------------------------------------------|-----------------------------------|-----------------------------------------------------------|-----------------------------------|---------------------------------|
| Crystal VC—Direct Samples  | 8 [10, 32, 34, 40, 45, 47, 50, 56] | 7243 (76–5865)           | 65.6 (52.7–77.1) to 100.0 (82.4–100.0)                   | 93.3 (83.7–97.5)                  | 60.0 (53.3–66.5) to 91.8 (81.9–97.3)                      | 77.7 (70.7–83.3)                  | 0.865                           |
| Crystal VC—Enriched Samples | 5 [10, 24, 30, 32, 40] | 1614 (100–673)           | 68.3 (51.9–81.9) to 98.9 (94.1–100.0)                    | 85.5 (68.1–94.4)                  | 90.0 (55.3–99.7) to 100.0 (94.4–100.0)                   | 98.3 (92.8–99.6)                  | 0.848                           |
| Cholera Screen—Direct Samples | 3 [25, 29, 39] | 250 (17–99)               | 98.0 (93.3–100.0) to 100.0 (69.2–100.0)                  | 98.6 (94.7–99.7)                  | 22.2 (6.4–47.6) to 100.0 (93.3–100.0)                   | 78.1 (18.9–98.2)                  | 0.966                           |
| IP dipstick—Direct Samples  | 2 [49, 59]          | 414 (102–172)             | 93.1 (84.5–97.7) to 98.5 (91.8–100.0)                    | 95.3 (91.1–97.5)                  | 77.0 (67.5–84.8) to 95.9 (88.6–99.2)                    | 87.4 (73.6–94.5)                  | 0.969                           |

1 One study undertaken in 2 separate locations so 4 results included
2 One study undertaken in 2 separate locations so 3 results included

https://doi.org/10.1371/journal.pone.0270860.t002
Table 3. Summary of findings: Sensitivity and specificity.

| Test                                      | Intended location | Diagnostic target—as reported in studies | Sample type | Enrichment step? | Reference | No. Studies | Study IDs | Sensitivity % (95% CI) | Specificity % (95% CI) |
|-------------------------------------------|-------------------|------------------------------------------|-------------|------------------|-----------|-------------|-----------|------------------------|------------------------|
| Immunologically-based tests detecting lipopolysaccharides or proteins |                   |                                          |             |                  |           |             |           |                        |                        |
| Artron RDT                                | Field             | Antigens of *V. cholerae* O1 and O139    | Stool       | No Culture       | 1         | Matias 2017 [45] |           | 98.6 (92.7–100)        | 69.1 (55.2–80.9)        |
| Bead ELISA                                | Laboratory        | Cholera toxin                            | Stool       | No Culture       | 3         | Ramamurthy 1996 [55] (mAb-based) |           | 69.9–84.7               | 63.6–81.8               |
|                                           |                   |                                          |             |                  |           | Ramamurthy 1996 [55] (pAb-based) |           | 81.8 (59–94)             |                        |
|                                           |                   |                                          |             |                  |           | Ramamurthy 1997 [54] |           | 63.6 (40.8–82)          |                        |
|                                           |                   |                                          |             |                  |           | Ramamurthy 1993 [54] |           | 79.2 (65.5–88.7)        |                        |
|                                           |                   |                                          |             |                  |           | Ramamurthy 1992 [53] |           | 81.3 (53.7–99)          |                        |
| BengalScreen                              | Field             | Lipopolysaccharide antigen of *V. cholerae* O139 | Stool       | No Culture       | 1         | Hasan 1995 [37] |           | 95 (71.9–99.7)          | 100 (75–100)            |
| Bengal DFA                                | Field             | Lipopolysaccharide antigen of *V. cholerae* O139 | Stool       | No Culture       | 1         | Hasan 1995 [37] |           | 100 (79.1–100)          | 100 (75–100)            |
| Bengal SMART                              | Field             | ‘A’ factor of *V. cholerae* O139         | Stool       | No Culture       | 1         | Qadri 1995 [52] |           | 97 (89.5–99.1)          | 100 (95.5–100)          |
| Cholera Screen                            | Field             | ‘A’ factor of *V. cholerae* lipopolysaccharide O1 | Stool       | No Culture       | 3         | 98–100 |           | 22.2–100               |                        |
|                                           |                   |                                          |             |                  |           | Colwell 1992 [29] (Guatemala) |           | 100 (65.5–100)          | 42.9 (11.8–79.8)         |
|                                           |                   |                                          |             |                  |           | Colwell 1992 [29] (Bangladesh) |           | 98 (88–99.9)            | 77.8 (57.3–90.6)         |
|                                           |                   |                                          |             |                  |           | Carillo 1994 [25] |           | 98.8 (92.4–99.9)        | 22.2 (7.4–48.1)          |
|                                           |                   |                                          |             |                  |           | Islam 1994 [59] |           | 100 (93.58–100)         | 90 (91.58–100)          |
| Cholkit                                   | Field             | Lipopolysaccharide antigen of *V. cholerae* O1 | Stool       | No Culture       | 2         | 97.4–97.7 |           | 87.4–96.5               |                        |
|                                           |                   |                                          |             |                  |           | Islam 2019 [46] |           | 79.4 (62.1–91.3)        | 87.4 (85.5–89.1)         |
|                                           |                   |                                          |             |                  |           | Sayeed 2018 [56] |           | 97.7 (88.4–99.9)        | 96.5 (88.6–99.6)         |
|                                           |                   | Lipopolysaccharide antigen of *V. cholerae* O1 | Stool       | Yes Culture      | 1         | Islam 2019 [40] |           | 66.7 (47.2–82.7)        | 94.4 (91.7–96.5)         |
| Co-agglutination test (COAT)              | Field             | Lipopolysaccharide antigens of *V. cholerae* O139 | Stool       | No Culture       | 1         | Qadri 1994 [51] |           | 92 (84.1–96.5)          | 100 (96.9–100)          |
| Cholera DFA                               | Laboratory        | ‘A’ factor of *V. cholerae* lipopolysaccharide O1 | Stool       | No Culture       | 1         | Hasan 1994a [35] |           | 100 (82.2–100)          | 100 (80.8–100)          |
| Cholera diagnostic kit (mAb-based dot-blot ELISA) | Field             | *V. cholerae* O1 antigen A                | Stool       | Yes Culture      | 1         | 95.2–100 |           | 100                   |                        |
|                                           |                   |                                          |             |                  |           | Supawat 1994 [57] (patients) |           | 100 (73.2–100)          | 100 (97.6–100)          |
|                                           |                   |                                          |             |                  |           | Supawat 1994 [57] (household contacts) |           | 95.2 (74.1–99.8)        | 100 (98.8–100)          |
| Cholera SMART                             | Field             | Antigen A of *V. cholerae* O1 lipopolysaccharide | Stool       | No Culture       | 3         | 58–100 |           | 95–100                 |                        |
|                                           |                   |                                          |             |                  |           | Bolanos 2004 [23] |           | 100 (74.7–100)          | 100 (71.7–100)          |
|                                           |                   |                                          |             |                  |           | Hasan 1994b [36] (Bangladesh) |           | 95.6 (76–99.8)           | 100 (80.8–100)          |
|                                           |                   |                                          |             |                  |           | Kalluri 2006 [42] (field techs) |           | 58 (46–71)              | 95 (91–98)              |
|                                           |                   |                                          |             |                  |           | Kalluri 2006 [42] (lab techs) |           | 83 (75–90)              | 88 (82–93)              |
|                                           |                   |                                          |             |                  |           | Antigen A of *V. cholerae* O1 lipopolysaccharide | Stool | No Cholera Screen | 1 | Hasan 1994b [36] (Mexico) | 100 (90.2–100) | 100 (92.8–100) |

(Continued)
Table 3. (Continued)

| Test | Intended location | Diagnostic target—as reported in studies | Sample type | Enrichment step? | Reference | No. Studies | Study IDs | Sensitivity % (95% CI) | Specificity % (95% CI) |
|------|------------------|------------------------------------------|-------------|-----------------|-----------|-------------|-----------|------------------------|------------------------|
| Crystal VC | Field | Lipopolysaccharide antigen of *V. cholerae* O1 and O139 | Stool | No | Bacterial Culture | 7 | Range of point estimates | 65.6–98.6 | 49.2–98.4 |
| | | | | | | | George 2014 [32] | 65.6 (52.7–77.1) | 91.8 (81.9–97.3) |
| | | | | | | | Page 2012 [50] (clinicians) | 93.8 (89.2–97.2) | 78.4 (59.6–98.7) |
| | | | | | | | Page 2012 [50] (lab techs) | 93.8 (88.3–96.6) | 85.2 (69.8–99.2) |
| | | | | | | | Ley 2012 [45] | 93.1 (88.7–96.2) | 49.2 (44.3–54.1) |
| | | | | | | | Mukherjee 2010 [47] | 91.70 (95% CI not available) | 72.90 (95% CI not available) |
| | | | | | | | Islam 2019 [40] | 72.2 (64.6–78.9) | 77.1 (73.9–82.2) |
| | | | | | | | Sayeed 2018 [56] | 97.3 (87.6–99.9) | 98.4 (92.0–99.9) |
| | | | | | | | Matias 2017 [45] | 98.6 (96.5–99.6) | 71.1 (64.6–76.9) |
| Lipopolysaccharide antigen of *V. cholerae* O1 and O139 | Stool | Yes | Bacterial Culture | 3 | Range of point estimates | 75–98.9 | 90–98.4 |
| | | | | | | | George 2014 [32] | 75 (62.6–85) | 98.4 (91.2–100) |
| | | | | | | | Bwire 2017 [24] | 98.9 (94.0–99.8) | 90 (55.5–99.7) |
| | | | | | | | Islam 2019 [40] | 68.3 (51.9–81.9) | 90.8 (88.1–92.9) |
| Lipopolysaccharide antigen of *V. cholerae* O1 and O139 | Stool | No | PCR | 2 | Range of point estimates | 94.4–97 | 75–79.7 |
| | | | | | | | Ontweka 2016 [10] | 94.4 (81.3–99.3) | 79.7 (67.8–88.7) |
| | | | | | | | Harris 2009 [34] | 97 (88.7–99.5) | 75 (56.2–87.9) |
| Lipopolysaccharide antigen of *V. cholerae* O1 and O139 | Stool | Yes | PCR | 2 | Range of point estimates | 86.1–89.3 | 98.9–100 |
| | | | | | | | Ontweka 2016 [10] | 86.1 (70.5–95.3) | 100 (94.4–100) |
| | | | | | | | Debes 2016 [30] | 89.3 (71.8–97.7) | 98.9 (97.8–99.6) |
| Lipopolysaccharide antigen of *V. cholerae* O1 and O139 | Stool | No | Culture or PCR | 1 | Range of point estimates | 88.2–91.9 | 82.6–88.6 |
| | | | | | | | Page 2012 [50] (clinicians) | 91.9 (87–95.4) | 82.6 (71.6–90.7) |
| | | | | | | | Page 2012 [50] (lab techs) | 88.2 (82.6–92.4) | 88.6 (78.7–94.9) |
| Lipopolysaccharide antigen of *V. cholerae* O1 and O139 | Water | Yes | Culture | 2 | Range of point estimates | 65.6–87 | 99.6–100 |
| | | | | | | | Rashid 2017 [1] | 65.6 (55.2–75) | 99.6 (99.2–99.9) |
| | | | | | | | Chakraborty 2013 [28] | 87 (74.9–94.3) | 100 (99–100) |
| Dot-blot ELISA | Laboratory | *V. cholerae* O1 antigen | Stool | No | Culture | 1 | Chacumpia 1995 [20] | 63 (53.1–71.3) | 97 (82–99.8) |
| | | | | | | | Chacumpia 1998 [27] | 100 (89.6–100) | 99.95 (99.8–99.9) |

(Continued)
| Test | Intended location | Diagnostic target—as reported in studies | Sample type | Enrichment step | Reference | No. Studies | Study IDs | Sensitivity % (95% CI) | Specificity % (95% CI) |
|------|------------------|------------------------------------------|-------------|----------------|-----------|-------------|-----------|-----------------------|------------------------|
| IP dipstick | Field | V. cholerae O1 lipopolysaccharide | Stool | No Culture | 3 | Range of point estimates | 93–98.5 | 67–95.9 |
| | | | | | | Wang 2006 [59] | 93 (87–99) | 77 (69–85) |
| | | | | | Kalluri 2006 [42] | 93 (87–97) | 67 (60–74) |
| | | | | | Kalluri 2006 [42] | 94 (88–98) | 76 (70–82) |
| | | | | | Nato 2003 [49] | 98.5 (90.7–99.9) | 95.9 (87.8–98.9) |
| | | | | | Nato 2003 [49] | 94.2 (83.1–98.5) | 84.0 (70.3–92.4) |
| Latex agglutination test | Field | Lipopolysaccharide antigen of V. cholerae O1 and O139 | Stool | No Culture | 1 | Range of point estimates | 97–97 | 92.4–97 |
| | | | | | Wang 2006 [59] | 97 (93–100) | 97 (95–100) |
| | | | | | Bhuiany 2003 [22] | 97 (88.7–99.5) | 92.4 (82.5–97.2) |
| | | | | | Bhuiany 2003 [22] | 100 (95–100) | 92.5 (82.7–97.2) |
| | | | | | Nato 2003 [49] | 92.6 (74.2–98.7) | 98.1 (92.8–99.7) |
| | | | | | Bhuiany 2003 [22] | 100 (94.4–100) | 33 (14.4–58.8) |
| Medicos dipstick | Field | V. cholerae O1 (exact target and mechanism unknown) | Stool | No Culture | 1 | Range of point estimates | 97–88 | 79–80 |
| | | | | | Kalluri 2006 [42] | 84 (77–91) | 79 (73–85) |
| | | | | | Kalluri 2006 [42] | 88 (81–94) | 80 (73–95) |
| Pathogen Detection Kit (PDK) | Field | Antigen A of V. cholerae O1 lipopolysaccharide | Stool | No Culture | 1 | Bolanos 2004 [23] | 100 (71.7–100) | 86 (56.2–97.5) |
| | | | | | SD Bioline | Field | Antigens of V. cholerae O1 and O139 | Stool | No Culture or PCR | 1 | Mwaba 2018 [48] | 90.9 (81.3–96.6) | 95.2 (89.1–98.4) |
| | | | | | Antigens of V. cholerae O1 and O139 | Stool | Yes Culture or PCR | 1 | Mwaba 2018 [48] | 95.5 (87.3–99.1) | 100 (96.5–100) |
| | | | | | Antigens of V. cholerae O1 and O139 | Stool | No Culture | 1 | Matias 2017 [45] | 81.1 (75.6–85.8) | 92.8 (88.4–95.9) |
| Two-tip dipstick ELISA (sandwich ELISA) | Field | V. cholerae O1 and O139 antigens | Stool | Yes Culture | 1 | Tuteja 2007 [58] | 100 (91.4–100) | 100 (82.2–100) |
| | | | | | V. cholerae O1 and O139 antigens | Water | Yes Culture | 1 | Tuteja 2007 [58] | 100 (31–100) | 100 (90.6–100) |
| | | | | | V. cholerae O1 and O139 antigens | Water | No Combination (culture or 2+ of colloidal gold assay, real time fluorescent PCR, Vch-UPT-LF) | 1 | Hao 2017 [53] | 100 (71.7–100) | 100 (94.5–100) |
| | | | | | Vibrio cholerae O139 antigen | Water | No As above | 1 | Hao 2017 [53] | 100 (19.8–100) | 99 (93.4–99.9) |

**PCR-based tests detecting genes or nucleic acids**

| Test | Laboratory | Diagnostic target | Sample type | Reference | No. Studies | Study IDs | Sensitivity % (95% CI) | Specificity % (95% CI) |
|------|------------|-------------------|-------------|-----------|-------------|-----------|-----------------------|------------------------|
| Multiplex PCR (with: O139-rfb primers—O139F-2, O139R-2; O1-rfb primers—O1F-2, O1R-2; cholera toxin primers—VCT1, VCT2) | Sayered 2018 [56] | V. cholerae O1 and O139 rfb-specific genes and the ctxA gene. | Stool | No Culture | 1 | 73.6 (58.5–85.7) | 97.2 (93.2–99.2) |
| | | V. cholerae O1 and O139 rfb-specific genes and the ctxA gene. | Stool | Yes Culture | 1 | 100 (88.6–100) | 95 (87.5–98.4) |
| PCR (with primers specific to espM gene) | Montaz 2013 [46] | epsM gene of V. cholerae | Water | Yes Culture | 1 | 100 (31–100) | 100 (98.9–100) |
| PCR (with primers specific to V. cholerae O1) | Ramamurthy 1993 [54] | Cholera Toxin gene of V. cholerae O1 | Stool | Yes Culture | 1 | 100 (93.5–100) | 55 (40.6–68.2) |
| PCR assay (with new primers O139-1 and O139-2) | Albert 1997 [21] | Chromosomal region of V. cholerae O139 | Stool | No Culture | 1 | 94 (84.7–98.1) | 100 (95.9–100) |

(Continued)
diagnostic kit, Pathogen Detection Kit (PDK), Bengal DFA, and latex agglutination tests. Studies assessing these tests included those using both stool and water samples, enriched and non-enriched samples, and culture and combination reference tests. Notably, the majority of these tests were assessed in only one study, thus little can be inferred in relation to the high sensitivity. However, three tests—Cholera SMART, the IP dipstick, and Cholera Screen—were assessed by more than one study, and a broader range of sensitivities was found. While a sensitivity of 100% was reported for Cholera SMART in Bolaños 2004 [23] and Hasan 1994b [36], Kalluri 2006 [42] reported a sensitivity of only 58% when the test was undertaken by field technicians (83% when undertaken by laboratory technicians). Additionally, 30% of samples were marked ‘indeterminate’ by field technicians. While Nato 2003 [49] found a sensitivity of 100% for the IP dipstick, when targeting the O139 lipopolysaccharide on directly tested samples, 92.6% was reported by Bhuiyan 2003 [22] when samples were enriched. Additionally, when the O1 lipopolysaccharide was targeted, a range of 93–98.5% was reported in three studies on direct samples [42, 49, 59] and 97% in two studies on enriched samples [22, 59].

Of those tests intended for laboratory use, the bead ELISA and dot-blot ELISA were reported in more than one study, although on different samples from the same study groups. The highest sensitivities were found for the Cholera DFA [35] and dot-blot ELISA [27]. Chacumpa 1998 [27] reported higher sensitivities for the dot-blot ELISA when stool samples were enriched versus directly tested (100% compared to 63%).

### Specificity
In field-based tests 100% specificity was reported in 14 sub-groups for 11 tests. Of these, only Crystal VC was found to have specificity of 100% by more than one study. Onteweka 2016 [10] reported 100% (95% CI: 94.4–100%) specificity in enriched stool samples with a PCR reference, and Chakraborty 2013 [28] (100% specificity, 95% CI 99–100%) in enriched water samples with a culture reference. Additionally, some tests had 100% specificities reported by one study, with much lower specificities reported by others: whilst one study (Islam 1994 [39]) reported specificity of 100% in the Cholera Screen test, notably low specificities were reported by two other studies: 42.9%

---

**Table 3. (Continued)**

| Test                                      | Intended location | Diagnostic target—as reported in studies | Sample type | Enrichment step? | Reference | No. Studies | Study IDs | Sensitivity % (95% CI) | Specificity % (95% CI) |
|-------------------------------------------|-------------------|------------------------------------------|-------------|------------------|-----------|-------------|-----------|------------------------|------------------------|
| TaqMan Array Card (singleplex real time PCR format) | Laboratory | toxR gene | Stool | No | Conventional assay | 1 | Liu 2013 [44] | 100 (59.8–100) | 100 (93.7–100) |
| Cholera SMART                             | Laboratory | Cholera toxin | Stool | No | Combination (2+ matching results among real-time PCR, VET-RPLA, and CT-RTCA) | 1 | Jin 2013 [41] | 90 (72.3–97.4) | 97 (89.1–99.5) |
| ChromID Vibrio                            | Laboratory | V. cholerae bacterial strains | Stool | No | Combination (by Vitek 2 and/or ID 32 E biochemical strips, PCR, or comparison of ChromID Vibrio with TCBS) | 1 | Eddabra 2011 [31] | 79 (48.8–94.3) | 100 (75.9–100) |
| TCBS                                      | Laboratory | V. cholerae bacterial strains | Stool | Yes | As above | 1 | Eddabra 2011 [31] | 100 (73.2–100) | 100 (75.9–100) |
|                                           | Laboratory | V. cholerae bacterial strains | Stool | No | As above | 1 | Eddabra 2011 [31] | 79 (48.8–94.3) | 50 (25.5–74.5) |

1Confidence Intervals calculated from raw numbers provided in paper
2Estimate calculated using Bayesian latent class modelling
3Exact target and mechanism unknown, assumed immunologically-based

https://doi.org/10.1371/journal.pone.0270860.t003

Cholera diagnosis in human stool and detection in water

PLOS ONE | https://doi.org/10.1371/journal.pone.0270860 July 6, 2022 14 / 27
(95% CI 11.8–79.8%) in Guatemala in Colwell 1992 [29], and 22.2% (95% CI 7.4–48.1%) in Carillo 1994 [25].

One laboratory-based test reported specificity of 100%: the Cholera DFA (Hasan 1994a [35]).

A number of studies reported tests with both 100% sensitivity and specificity: Cholera SMART (when direct stool samples tested with Cholera Screen reference, in Hasan 1994b [36]); the two-tip dipstick ELISA (both enriched and direct stool samples, in Tuteja 2007 [58]), Cholera Screen (on direct stool samples with bacterial culture reference, in Islam 1994 [39]), the Vch-UPT-LF (when targeting the O1 antigen, Hao 2017 [33]), the Bengal DFA (Hasan 1995 [37]), and the Cholera DFA (Hasan 1994a [35]). However, these results where only found in single studies.

**PCR-based tests.** All but one of the five PCR tests were assessed by only one study, which limits interpretation. However, four of five studies reported sensitivity of 100%. In Albert 1997 [21], the PCR assay with new primers O139-1 and O139-2 had a sensitivity of 94%. In the Multiplex PCR, where two studies reported results, Hoshino 1998 [38] reported sensitivity of 100% on enriched samples, whereas Sayeed 2018 [56] reported sensitivity of 73.6% on direct samples (where sensitivity was estimated using Bayesian latent class modelling).

Three of the five tests had specificity of 100%, with the remaining two reporting specificities of 55% (PCR with unspecified primers specific to *V. cholerae* [54]), and 95–97.2% (Multiplex PCR, enriched and direct samples respectively [38, 56]).

The TaqMan Array Card was assessed against both a conventional assay and PCR Luminex reference, and was found to have sensitivity and specificity of 100% in both instances [44].

**Other test types: Selective media-based tests and real-time cell analysis.** One study investigated selective media-based tests—the ChromID Vibrio, and Thiosulfate-Citrate-Bile Salts-Sucrose (TCBS) agar [31]. In both tests, direct stool samples had lower sensitivities than enriched samples (79% versus 100%, respectively). ChromID Vibrio appeared to be more specific than TCBS for both enriched and directly tested samples (100% versus 50%).

One study reported on a cholera-toxin real-time cell analysis, reporting sensitivity and specificity of 90% and 100%, respectively [41].

**Results: Other characteristics of included tests**

**Price.** Price was not well reported across diagnostic tests, with information only available for four of 21 immunologically-based tests and one of five PCR-based tests. Price was reported by multiple papers for Crystal VC, and one paper each for Cholera SMART, the Medicos dipstick, and the SD Bioline. Of these, Crystal VC was the cheapest at approximately USD $1.90, per test [1, 32, 34, 43] and Cholera SMART the most expensive at USD $14 per test [42]. In contrast, the one PCR test with price available was considerably more expensive: the TaqMan Array Card was USD $60 per card [44]. However, it was unclear from the text how many samples a single TaqMan Array Card could process.

**Test time.** Test time was similarly more comprehensively reported across immunologically-based tests than PCR-based tests. Immunologically-based tests ranged in testing time from two minutes (Pathogen Detection Kit [23]) or less than five minutes (Cholera Screen [29, 39] and BengalScreen [37]) to 3.5 hours (Bead ELISA [53]). Tests intended for field use reported times between two minutes and less than two hours [23, 57], and tests intended for laboratory detection reported times from less than 30 minutes to 3.5 hours [35, 53]. The two-minute estimate for the Pathogen Detection Kit was for samples that were clinically deemed to have a high probability of cholera [23].
PCR-based tests generally did not specify turnaround time, with the exception of the Multiplex PCR [38] which took approximately five hours.

**Ease of use and training.** No information on ease of use or training was provided for PCR-based tests, however given these were all laboratory-based we can assume technical skill was required. Multiple studies reported ease of use for a number of different immunologically-based tests, however few specifics were given beyond ‘simple’ or ‘easy to use’, or ‘easy to perform’ [29, 37]. The exception to this was Kalluri 2006 [42] reporting on the Cholera SMART: while Hasan 1994b [36] described the test as simple and easy to use, users in Kalluri 2006 [42] reported that “the SMART device was often difficult to interpret and was frustrating to use”.

**Other test features—Storage, internal quality control, result capturing.** Where reported, immunologically-based tests displayed results as coloured lines or spots on the device [39, 43, 45, 52], and PCR-based tests as bands on a gel electrophoresis or plate [21, 38]. All studies including information about quality control included some sort of positive and/or negative control included in the test. Information on storage was not well reported, with information only available for six tests.

Further details regarding other characteristics of included tests can be found in Table 4.

**Risk of bias and applicability**

Risk of bias was assessed using the QUADAS-2 framework [19].

Sample selection was deemed low to unclear risk of bias across studies; studies assessed as unclear were graded so due to a paucity of information on selection in the record. All studies providing information on sample selection were assessed as low risk.

Risk of bias in the interpretation of the index test was assessed as high in 13 studies. In all of these, this relates to applicability concerns, as the intended location of the test did not match the location in which the study evaluated that test, as assessed by reviewers. The remaining studies were rated unclear, where information was missing, or low. Only eight studies specified that blinding was used for interpretation of test results, and one study specified that it was not used. The remaining studies were unclear.

Risk of bias in the test conduct and interpretation of the reference test was assessed as low in all but three studies. In Hao 2017 [33], Jin 2013 [41] and Eddabra 2011 [31], risk of bias was graded unclear, due to the use of complex combination references, in which two of three different test methods were required to be positive. While the remainder of the studies were graded low risk, the majority used a bacterial culture reference. The low grade was deemed appropriate as bacterial culture is considered the gold standard in cholera diagnosis; however, it has recognised limitations due to its low sensitivity (as low as 70.8% reported in Sayeed 2018 [56]). Five studies specified that reference tests were undertaken in a blinded manner, with the remaining studies being unclear.

Sample flow refers to whether samples received the same reference standard, and whether all samples were included in the analysis. While all studies used reference standards consistently across samples, three studies (Debe 2016 [30], Liu 2013 [44], Matias 2017 [45]), did not include all samples in their analysis, and did not report reasons for this exclusion.

The results of the risk of bias and applicability assessment are shown in Fig 2. A full table of results for individual studies is available in S6 Appendix.

**Discussion**

This review found 41 studies reporting on 28 different tests for cholera diagnosis and detection. The majority of these tests were immunologically-based and intended for field settings. Diagnostic accuracy of different tests appeared broadly similar, with 22 tests having both
Table 4. Other test characteristics.

| Test Name                          | Intended location of test | Developer                                      | References | Test time (excl. any sample enrichment) | Price | Internal quality control | Result capturing | Notes on ease of use, training, maintenance etc. | Storage |
|-----------------------------------|---------------------------|------------------------------------------------|------------|----------------------------------------|-------|--------------------------|-----------------|------------------------------------------------|---------|
| Immunologically-based tests        |                           |                                                 |            |                                        |       |                         |                 |                                                 |         |
| detecting lipopolysaccharides or  |                           |                                                 |            |                                        |       |                         |                 |                                                 |         |
| proteins                           |                           |                                                 |            |                                        |       |                         |                 |                                                 |         |
| Artron RDT                        | Field                     | Artron Laboratories Inc., Canada                | [45]       | 15 minutes                             | Not specified | Control line             | Three lines—two test and a control | Not specified      | Not specified          |
| Bead ELISA                        | Laboratory                | Not specified                                  | [53–55]    | Assay can be performed in 3.5 hours   | Not specified | Control included         | Not specified      | Described as "easy to perform"                  | Not specified |
| BengalScreen                      | Field                     | New Horizons Diagnostics                       | [37]       | <5 minutes                             | Not specified | Positive and negative controls included | Visible agglutination in test circle | Described as simple and easy to use with no need for trained personnel | Not specified |
| Bengal DFA                        | Field                     | New Horizons Diagnostics                       | [37]       | <20 minutes                            | Not specified | Positive and negative controls included | Not specified      | Not specified          |
| Bengal SMART                      | Field                     | New Horizons Diagnostics                       | [52]       | <15 minutes                            | Not specified | Not specified            | Appearance of coloured spots | Not specified          | Does not require refrigeration |
| Cholera Screen                    | Field                     | New Horizons Diagnostics Corp., Columbia, Md.  | [25, 29, 40]| <5 minutes                             | Not specified | Positive and negative controls included | Circles marked on a slide | Described as simple [29] and with little training required [25] | Not specified |
| Cholkit                           | Field                     | Developed by study group                       | [40, 56]   | 15 minutes                             | Not yet commercially available [40] | Control line             | Two lines—a test and control | Not specified          | Not specified          |
| Co-agglutination Test (COAT)      | Field                     | Not specified                                  | [51]       | A few minutes                          | Not specified | Control reagent included | Two ‘regions’ one control and one test region | Described as ‘simple’                  | Not specified |
| Cholera DFA                       | Laboratory                | Not specified                                  | [35]       | <30 minutes to complete staining process | Not specified | Positive and negative controls included | Appearance of yellow V. cholerae colonies | Described as ‘simple’                  | Not specified |
| Cholera diagnostic kit            | Field                     | Not specified                                  | [57]       | <2 hours                               | "Approximately one-fourth of that of the culture method" | Positive and negative control antigens included | Appearance of coloured spot indicates positive reaction | Described as "relatively simple to perform"; technicians in study received two days training. | Not specified |
| (mAb-based dot-blot ELISA kit)    |                           |                                                 |            |                                        |       |                         |                 |                                                 |         |
| Cholera SMART                     | Field                     | New Horizons Diagnostics Corp., Columbia, Mary., USA | [23, 36, 42]| 10–15 minutes according to manufacturers. However, one study [42] reported mean field time as 19 minutes (range 5–40 minutes) | $14 | Negative control spot | Two spots—a test and a control | Described as simple and easy to use by one study [36], conversely other users reported that "the SMART device was often difficult to interpret and was frustrating to use" [42]. No or little training required [23, 36], although offered in one study [42]. | Unclear: refrigeration for long-term storage reported [42], as well as unrefrigerated storage from up to a year at room temperature [36] |

(Continued)
Table 4. (Continued)

| Test Name                  | Intended location of test | Developer                          | References | Test time (excl. any sample enrichment) | Price | Internal quality control | Result capturing | Notes on ease of use, training, maintenance etc. | Storage |
|----------------------------|---------------------------|------------------------------------|------------|----------------------------------------|-------|--------------------------|-----------------|------------------------------------------------|---------|
| Crystal VC                 | Field                     | Span Diagnostics, Surat, India (originally Institut Pasteur) | [1, 10, 24, 28, 30, 32, 34, 40, 43, 45, 47, 50, 56] | 10–20 mins | $1.90 per test | Control line present | Three lines—two test lines and a control line | Described as 'simple' and 'easy to perform' [24, 30, 34, 43]. Half day [1, 32], to 2-day training given [10]. Others used illustrated instructions [34, 43]. Some untrained users had difficulty differentiating O1 and O139 test lines [50]. One study [50] reports that training users had no impact on test sensitivity; specificity was lower in untrained users, however difference was not statistically significant. | Stable between 4–30˚C and in humid conditions. |
| Dot-blot ELISA             | Laboratory                | Not specified                      | [26, 27]   | 90 minutes [27] or between 1–3 hours [26] | 'Inexpensive' | Positive and negative controls included | Appearance of coloured spots—colour of which determined results | Described as "easy to perform" | Not specified |
| IP dipstick                | Field                     | Institut Pasteur, Paris, France    | [22, 42, 49, 59] | 10 mins reported by manufacturer. In practice in field mean 16 min (range 3–58 mins) [42] | Not yet commercially available | Control line Two lines—a test and control | Test requiring 'little technical experience' [22], and lab and field technicians reported easy to use [42]. Training was reported in some studies [22, 42]. | Storage at room temperature [22, 42]; stable for 21 days at 60˚C, 4˚C, -20˚C and -80˚C [49] | Not specified |
| Latex agglutination test   | Field                     | Denka Seiken, Tokyo, Japan         | [23]       | “Rapid” | Not specified | Not specified | Not specified | Reported that little training required | Refrigeration for long-term storage |
| Medicos dipstick           | Field                     | Advanced Diagnostics Inc., South Plainfield, NJ, USA | [42]       | 10 mins reported by manufacturer. In practice mean time in field 23 mins (range 7–54 mins) | $4 per test | Not specified | Not specified | Reported easy to use and interpret; training given in study | Not specified |
| Pathogen Detection Kit (PDK) | Field                   | Intelligent Monitoring Systems, Gainesville, Florida, USA | [23]       | 2 mins in samples with high probability of cholera | Not specified | Not specified | Visualized on nitrocellulose membrane | Ease of use not specified, but highly qualified technical personnel not required | Not specified |
| SD Bioline                 | Field                     | Standard Diagnostics Inc., Korea   | [45, 48]   | 10–20 minutes | Approx. €2 per test | Control line Three lines—two test and a control | Matches recommendations on ease of use | Not specified | Not specified |
| Two-tip dipstick sandwich ELISA | Field            | Not specified                      | [58]       | Not specified | Not specified | Not specified | Appearance of coloured dots | Described as simple | Not specified |

(Continued)
| Test Name                        | Intended location of test | Developer            | References | Test time (excl. any sample enrichment) | Price | Internal quality control | Result capturing | Notes on ease of use, training, maintenance etc. | Storage |
|---------------------------------|---------------------------|----------------------|------------|----------------------------------------|-------|--------------------------|-----------------|------------------------------------------------|---------|
| Vch-UPT-LF                      | Field                     | Not specified        | [33]       | Not specified                          | Not specified | Control line present    | Three lines—two test lines and a control line | Not specified                           | Not specified |
| **PCR-based tests detecting genes or nucleic acids**                                                                                                                             |
| Multiplex PCR (with: O139-rfb primers—O139F-2, O139R-2; O1-rfb primers—O1F-2, O1R-2; cholera toxin primers—VCT1, VCT2) | Laboratory                | Not specified        | [38, 56] | ~5 hours                              | Requires "expensive reagents" [56] | Positive and negative controls included | Bands on a plate | Requires "trained laboratory staff" [56] | Not specified |
| PCR (with primers specific to espM gene)                                                                                                                                          |
| Laboratory                      | Not specified             | [46]                 | "fast"     | Not specified                          | Not specified | Not specified            | Not specified                           | Not specified                           | Not specified |
| PCR (with primers specific to V. cholera O1)                                                                                                                                     |
| Laboratory                      | Not specified             | [54]                 | Not specified | Not specified                          | Not specified | Not specified            | Not specified                           | Not specified                           | Not specified |
| PCR assay (with new primers O139-1 and O139-2)                                                                                                                                    |
| Laboratory                      | Not specified             | [21]                 | Not specified | Not specified                          | Positive and negative controls run alongside test samples | Bands on gel electrophoresis | Not specified                           | Not specified                           | Not specified |
| TaqMan Array Card (singleplex real time PCR format)                                                                                                                                 |
| Laboratory                      | Life Technologies        | [44]                 | "Significantly shorter than that of conventional methods" | $60 for TAC | Assays spotted in duplicate and two positive controls and a negative control included | Not specified                           | Not specified                           | Not specified                           | Not specified |
| **Other test types: real-time cell analysis, and selective media-based tests**                                                                                                        |
| Cholera toxin real-time cell analysis                                                                                                                                                |
| Laboratory                      | RTCA system from ACEA Biosciences, San Diego, CA | [41]                 | Inoculation to detection time 0.89±0.51 h | Not specified | Not specified | Not specified                          | Not specified                           | Not specified                           | Not specified |
| ChromID Vibrio                                                                                                                                                                      |
| Laboratory                      | bioMérieux, Marcy l'Etoile, France | [31]                 | Not specified | Not specified                          | Not specified | Appearance of blue-green bacterial colony | Not specified                           | Plates stored at 4˚C                      | Not specified |
| TCBS medium                                                                                                                                                                         |
| Laboratory                      | Bio-Rad (Marnes-La-Coquetté, France) | [31]                 | Not specified | Not specified                          | Not specified | Appearance of blue-green bacterial colony | Not specified                           | Not specified                           | Not specified |

https://doi.org/10.1371/journal.pone.0270860.t004
sensitivities and specificities above 95% reported by at least one study. However, accuracy was difficult to compare directly due to variations in sample handling and setting in which tests were assessed. Additionally, low sample sizes limited the validity of some assessments, particularly in those 10 studies where sample size was less than 100.

**Meta-analysis**

The three tests for which meta-estimates were available (Crystal VC on direct samples and enriched samples; Cholera Screen on direct samples; and IP dipstick on direct samples), showed good diagnostic accuracy. Sensitivity meta-estimates ranged from 85.5% (68.1–94.4%) in Crystal VC on enriched samples, to 98.6% (94.7–99.7%) in the Cholera Screen test on direct samples. Specificity meta-estimates ranged from 77.7% (70.7–83.3%) in Crystal VC on direct samples, to 98.3% (92.8–99.6%) in Crystal VC on enriched samples. However, heterogeneity was seen across studies in all four meta-analyses, in particular in the sensitivities reported for Crystal VC (both on direct and enriched samples), and the specificities reported for Cholera Screen.

When interpreting sensitivity and specificity results it is critical to recognise that these are paired outcomes, which tend to be inversely correlated [60]. For this reason, statistical methods such as calculation area under the curve (AUC) and diagnostic odds ratios (DOR) are preferred, though less intuitive to interpret.

Area under the curve (AUC) estimates were all above 0.8, with two tests having estimates above 0.95 (Cholera Screen and IP dipstick), demonstrating these tests provided correct diagnoses over 95% of the time. However, the inclusion of only a small number of studies prompts caution over AUC results [61], particularly in the meta-analyses of the Cholera Screen and IP dipstick tests, where only four and three data points were included, respectively. Additionally, a high area under the curve can occur even with studies with very high specificities but low sensitivities (e.g., Carillo 1994 [25] in the Cholera Screen meta-analysis, reporting a sensitivity of only 22%).
DOR results can be found in S3 Appendix.

Narrative synthesis: Factors affecting sensitivity and specificity

The narrative synthesis completed for all reported products indicated that multiple tests had at least one study reporting both sensitivity and specificity of over 90%. For example, for field-based tests on stool samples with no enrichment step, this included nine tests (BengalScreen, Bengal DFA, Bengal SMART, Cholera Screen, Cholkit, Cholera SMART, Crystal VC, IP dipstick and SD Bioline). However, wide variation was seen across studies, and several factors prompt caution over interpretation of sensitivity and specificity results. While bacterial culture is considered the gold standard in cholera diagnostics due to its high specificity, sensitivity is reportedly low [10, 50, 56]. This creates a situation whereby the index test may be more sensitive than the reference standard, leading to an underestimation of index test specificity; thus, accuracy of index tests assessed only against bacterial culture should be interpreted with this in mind. A couple of solutions have been used to overcome this. First, using combination references, such as culture alongside PCR [48, 50]. Second, use of Bayesian latent class analysis, which considers prior information regarding accuracy of bacterial culture (as used by Sayeed 2018 [56] and Page 2012 [50]).

The majority of tests reviewed are intended for use in the field, in cholera outbreak situations. However, the studies often assessed tests in alternate settings, such as in a lab using field samples [28, 45]. There was some evidence that studies that did assess tests in ‘real’ field settings found lower sensitivities and specificities than those using alternate settings. For example, for the Cholera SMART test, Kalluri 2006 [42] reported sensitivity of 58% during a field setting whereas Bolaños 2004 [23] reported sensitivity of 100% during laboratory assessment. However, Hasan 1994b [36], assessing the Cholera SMART in a field trial undertaken at a research centre (International Centre for Diarrhoeal Disease Research, Bangladesh) reported sensitivities of 95.6–100%. Moreover, this pattern is not seen across all tests: the Crystal VC results show no clear association between studies in contexts that match intended use, and those that do not. Ley 2012 [43] explicitly compared performance of the Crystal VC in the laboratory and the field, using the same samples, finding sensitivity and specificity of 90% and 55.6%, respectively, in the field, and 87.5% and 74.1%, respectively, in the laboratory. However, this difference was not statistically significant. Mukherjee 2010 [47] reports that the specific conditions of the field may also be impactful: during monsoon season, when V. cholerae cases were more prevalent, sensitivity and specificity of Crystal VC was 100% and 87.3%, compared to 88% and 61% during the post-monsoon and winter season when V. cholerae cases were less prevalent.

Finally, the skill level of the tester may affect test performance: Kalluri 2006 [42] found a sensitivity and specificity for Cholera SMART of 58% and 95%, respectively, when the test was undertaken by field technicians, but 83% and 88%, when undertaken by lab technicians. The study by Page 2012 [50] assessed performance of Crystal VC when undertaken by laboratory technicians and clinicians. Using Bayesian analysis, sensitivity and specificity of 93% and 85.3% was reported when undertaken by laboratory technicians, compared with 93.8% and 78.4% when undertaken by clinicians. However, these differences in specificity were not statistically significant [50].

Narrative synthesis: Other product characteristics

Other characteristics of tests were generally poorly reported on in studies. However, a limited number of studies did report on factors such as cost, turnaround time, and ease of use – major factors which affect how tests perform in practice. Given the similarity in diagnostic accuracy results of many of the tests, it is the intended setting of a product and the product’s other
technical or usability characteristics that are likely to drive decisions over which test is most appropriate in a given situation. For example, if diagnostic test cost is the ultimate factor affecting utility of a test in developing countries (as suggested by Kalluri 2006 [42]), the Crystal VC (costing $1.90 per test), or the SD Bioline (at approximately €2 per test) are the cheapest—although, any sample enrichment required will somewhat increase this cost. If turnaround time is prioritised, the Cholera Screen and the Pathogen Detection Kit have the fastest reported times, both at under 5 minutes [23, 29, 39].

Sample enrichment additionally affects turnaround time. The estimates reported in Table 4 for test time do not include enrichment time, despite numerous studies using samples enriched in Alkaline Peptone Water (APW) prior to testing [10, 24, 30, 32, 40]. Enrichment time varied from four hours in APW (Crystal VC [10]; two-tip dipstick ELISA [58]; Cholera diagnostic kit [57]; IP dipstick [22]; SD Bioline [48]) to 24 hours in APW (Crystal VC [28, 30]), which significantly increases the turnaround time of RDTs for which it may be required. Additionally, reported test-time estimates were manufacturer specified, rather than assessed by the independent evaluators. Kalluri 2006 [42] assessed the manufacturer’s specification versus actual field time taken for three tests and reported that: Cholera SMART had a 10–15 minute specification whereas actual field time ranged from five to 40 minutes (mean 19 minutes); the IP dipstick had a 10-minute specification but took between three and 58 minutes in the field (mean 16 minutes); and the Medicos dipstick had a 10 minute specification but in practice took between seven and 54 minutes (mean 23 minutes).

There was insufficient evaluation around ease of use and training requirements to draw out which tests were considered the most useable. While many studies briefly described tests as ‘simple’ or ‘easy to use’, it was not clear whether this information came from independent evaluation or manufacturer specifications. When usability was evaluated in studies, results appeared more mixed—for example with untrained users of the Crystal VC reporting difficulties differentiating O1 and O139 test lines [50], and laboratory and field technicians using Cholera SMART reporting that the device was “often difficult to interpret and was frustrating to use” [42].

Results in the context of previous reviews

This review—using a systematic review methodology—confirms the breadth of RDTs available for cholera detection with acceptable sensitivity and specificity suggested by previous non-systematic reviews [11, 13, 14]. However, the range of scores achieved for the same tests in different studies and contexts of use reinforces concerns regarding small sample sizes raised by Dick et al. [11] and the lack of field evaluation of kits indicated by both Ramamurthy et al. [13] and Dick et al. [11].

Limitations

To our knowledge, this is the first systematic review and meta-analysis on products for the diagnosis and detection of cholera to have been undertaken. Eleven databases of published and grey literature were searched, along with reference lists of identified studies, to capture as many relevant studies as possible. Despite this, some papers may have been missed in searches and not have been included. Additionally, given our search of predominantly English language databases, and problems accessing papers in alternate languages, our results show an Anglophone bias. As noted, data extraction from—and interpretation of—many studies was constrained by lack of detail in reports (including failure to comply with the Standards for Reporting of Diagnostic Accuracy (STARD) guidelines [62]).
Conclusions

Our findings indicate a number of actions that would strengthen the evidence-base regarding diagnostic test accuracy for cholera using water and still samples. For example, best practice is reflected in studies that include multiple index tests on the same samples, against a reference test, rather than assessing a single index test (for example as per Sayeed 2018 [56], Matias 2017 [45], and Bolaños 2004 [23]). Additionally, given limitations with culture as a reference, combination references using culture and PCR, or alternate methods of analysis, such as Bayesian methods, which take into account prior information regarding reference test accuracy, are of particular value (as in Sayeed 2018 [56] and Page 2012 [50]).

More generally, studies need to engage much more systematically with factors that may constrain the use and accuracy of diagnostic tests in field conditions in the low-resource settings where cholera may constitute a particular risk. This includes greater emphasis on studies of sensitivity and specificity in relevant field settings (such as those by Ontweka 2016 [10], Islam 2019 [40], Page 2012 [50] and Supawat 1994 [57]); however, it is not limited to this. With limited use of RDTs for either cholera surveillance or outcome detection [15], studies of barriers to use at scale are required. In contexts of extreme poverty, where most individuals will be earning under $2.00 per day, even the tests identified here as the cheapest are likely to be experienced as unaffordable at scale. Equally, evidence of decrements in test accuracy when conducted by staff with lesser levels of training—especially when tests are presented as ‘simple to use’—points to the importance of formal usability testing [63, 64] to establish threshold competence for reliable use. Turnaround times for test results also warrant rigorous analysis given the constraints of access, transport, and communications in many low-resource settings. For point-of-care use in such settings, evidence reviewed here suggests the value of formally establishing a test maintaining attainable ‘best in class’ performance of 90%+ sensitivity and specificity with a reliable turnaround time of under 10 minutes, while making little demand of technical expertise or laboratory facilities at cost of appreciably under $2.00 per unit.

Supporting information

S1 Appendix. PRISMA-DTA checklist.
(PDF)

S2 Appendix. Search strategies.
(PDF)

S3 Appendix. Additional meta-analysis results.
(PDF)

S4 Appendix. Summary of findings of individual studies.
(PDF)

S5 Appendix. Dataset.
(XLSX)

S6 Appendix. Risk of bias and applicability results.
(PDF)

Acknowledgments

The authors acknowledge the support of staff of the Cornish Lab in the Department of Biological Sciences at Columbia University and of the Institute of Global Health and Development at Queen Margaret University, Edinburgh in the completion of this work.
Author Contributions

Conceptualization: Jennifer Falconer, Karin Diaconu, Joseph Matragrano, Berthe-Marie Njanpop-Lafourcade, Alastair Ager.

Formal analysis: Jennifer Falconer.

Funding acquisition: Alastair Ager.

Investigation: Jennifer Falconer, Karin Diaconu, Fiona O’May, Advaith Gummaraju, Ifeyinwa Victor-Uadiale.

Methodology: Jennifer Falconer, Karin Diaconu.

Supervision: Karin Diaconu, Alastair Ager.

Writing – original draft: Jennifer Falconer.

Writing – review & editing: Karin Diaconu, Joseph Matragrano, Berthe-Marie Njanpop-Lafourcade, Alastair Ager.

References

1. Rashid M-U, Rahman Z, Burrowes V, Perin J, Mustafiz M, Monira S, et al. Rapid dipstick detection of Vibrio cholerae in household stored and municipal water in Dhaka, Bangladesh: CHoBI7 trial. Trop Med Int Health. 2017; 22: 205–209. https://doi.org/10.1111/tmi.12797 PMID: 27754582

2. Lemaitre J, Pasetto D, Perez-Saez J, Sciarra C, Wamala JF, Rinaldo A. Rainfall as a driver of epidemic cholera: Comparative model assessments of the effect of intra-seasonal precipitation events. Acta Trop. 2019; 190: 235–243. https://doi.org/10.1016/j.actatropica.2018.11.013 PMID: 30465744

3. Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. The Lancet. 2017; 390: 1539–1549. https://doi.org/10.1016/S0140-6736(17)30559-7

4. Ali M, Nelson AR, Lopez AL, Sack DA. Updated Global Burden of Cholera in Endemic Countries. PLoS Negl Trop Dis. 2015; 9: e0003832. https://doi.org/10.1371/journal.pntd.0003832 PMID: 26043000

5. Ganesan D, Gupta SS, Legros D. Cholera surveillance and estimation of burden of cholera. Vaccine. 2020; 38 Suppl 1: A13–A17. https://doi.org/10.1016/j.vaccine.2019.07.036 PMID: 31326254

6. D’Mello-Guyett L, Gallandat K, Van den Bergh R, Taylor D, Built G, Legros D, et al. Prevention and control of cholera with household and community water, sanitation and hygiene (WASH) interventions: A scoping review of current international guidelines. PLoS ONE. 2020; 15. https://doi.org/10.1371/journal.pone.0226549 PMID: 31914164

7. Spiegel P, Ratnayake R, Hellman N, Verver M, Ngwa M, Wise PH, et al. Responding to epidemics in large-scale humanitarian crises: a case study of the cholera response in Yemen, 2016–2018. BMJ Glob Health. 2019; 4. https://doi.org/10.1136/bmjgh-2019-001709 PMID: 31406596

8. Legros D, Partners of the Global Task Force on Cholera Control. Global Cholera Epidemiology: Opportunities to Reduce the Burden of Cholera by 2030. J Infect Dis. 2018; 218: S137–S140. https://doi.org/10.1093/infdis/jiy486 PMID: 30184102

9. Federspiel F, Ali M. The cholera outbreak in Yemen: lessons learned and way forward. BMC Public Health. 2018; 18: 1338. https://doi.org/10.1186/s12889-018-6227-6 PMID: 30514336

10. Ontweka LN, Deng LO, Rauzier J, Debes AK, Tadesse F, Parker LA, et al. Cholera rapid test with enrichment step has diagnostic performance equivalent to culture. PLoS ONE. 2016; 11. https://doi.org/10.1371/journal.pone.0168257 PMID: 27992488

11. Dick MH, Guillerm M, Moussy F, Chaignat C-L. Review of Two Decades of Cholera Diagnostics—How Far Have We Really Come? PLoS Negl Trop Dis. 2012; 6: e1845. https://doi.org/10.1371/journal.pntd.0001845 PMID: 23071851

12. Roadmap 2030–Global Task Force on Cholera Control. [cited 28 Apr 2022]. https://www.gtfcc.org/about-gtfcc/roadmap-2030/

13. Ramamurthy T, Das B, Chakraborty S, Mukhopadhyay AK, Sack DA. Diagnostic techniques for rapid detection of Vibrio cholerae O1/O139. Vaccine. 2020; 38: A73–A82. https://doi.org/10.1016/j.vaccine.2019.07.066 PMID: 31427135

14. Tarh JE. A Review on Diagnostic Methods for the Identification of Vibrio cholerae. J Adv Med Res. 2020; 136–164. https://doi.org/10.9734/jammr/2020/v32i830474
15. Learoyd TP, Gaut RM. Cholera: under diagnosis and differentiation from other diarrhoeal diseases. J Travel Med. 2018; 25: S46–S51. https://doi.org/10.1093/jtm/tyx017 PMID: 29718439

16. Diaconu K, Falconer J, O’May F, Jimenez M, Matragrano J, Njanpop-Lafourcade B, et al. Cholera diagnosis in human stool and detection in water: protocol for a systematic review of available technologies. Syst Rev. 2018; 7: 29. https://doi.org/10.1186/s13643-018-0679-8 PMID: 29458416

17. Ostrov N, Jimenez M, Billerbeck S, Brisbois J, Matragrano J, Ager A, et al. A modular yeast biosensor for low-cost point-of-care pathogen detection. Sci Adv. 2017; 3: e1603221. https://doi.org/10.1126/sciadv.1603221 PMID: 28782007

18. McInnes MDF, Moher D, Thoms BD, McGrath TA, Bossuyt PM, and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018; 319: 388–396. https://doi.org/10.1001/jama.2017.19163 PMID: 29362800

19. University of Bristol. QUADAS-2. University of Bristol; [cited 30 Jan 2021]. https://www.bristol.ac.uk/population-health-sciences/projects/quadas/quadas-2/

20. Shim SR, Kim S-J, Lee J. Diagnostic test accuracy: application and practice using R software. Epidemiol Health. 2019; 41. PMID: 30999739

21. Albert MJ, Islam D, Nahar S, Qadri F, Falklind S, Weintraub A. Rapid detection of Vibrio cholerae O139 bengal from stool specimens by PCR. J Clin Microbiol. 1997; 35: 1633–1635. https://doi.org/10.1128/JCM.35.6.1633-1635.1997 PMID: 9163504

22. Bhuiyan NA, Qadri F, Faruque ASG, Malek MA, Salam MA, Nato F, et al. Use of dipsticks for rapid diagnosis of cholera caused by Vibrio cholerae O1 and O139 from rectal swabs. J Clin Microbiol. 2003; 41: 3939–3941. https://doi.org/10.1128/JCM.41.8.3939-3941.2003 PMID: 12904424

23. Bolaños HM, Acuña MT, Serrano AM, Obando X, Mairena H, Cháves L, et al. Performance of Cholera-SMART® and Pathogen-Detection-Kit® in the quick diagnosis of cholera. Rev Panam Salud PublicaPan Am J Public Health. 2004; 16: 233–241.

24. Bwire G, Orach CG, Abdallah D, Debes AK, Kagirita A, Ram M, et al. Alkaline peptone water enrichment with a dipstick test to quickly detect and monitor cholera outbreaks. BMC Infect Dis. 2017; 17: 1–8. https://doi.org/10.1186/s12879-017-2824-8 PMID: 29157211

25. Carillo L, Gilman RH, Mantle RE, Nunez J, Moron J, et al. Rapid detection of Vibrio cholerae O1 in stools of Peruvian cholera patients using monoclonal immunodiagnostic kits. Loya Cholera Working Group in Peru. J Clin Microbiol. 1994; 32: 856–857. https://doi.org/10.1128/JCM.32.3.856-857.1994 PMID: 8195409

26. Chaicumpa W, Thatthiyaphong A, Supawat K, Chonsa-nguan M, Kalambaheti T, Eampongkalap B, et al. Rapid detection of V. cholerae O1. Serodiagn Immunother Infect Dis. 1995; 7: 161–172. https://doi.org/10.1016/0888-0786(95)8279-7

27. Chaicumpa W, Sriramote P, Sakolvaree Y, Kalambaheti T, Chonsa-Nguan M, Taphaisiri P, et al. Rapid diagnosis of cholera caused by Vibrio cholerae O139. J Clin Microbiol. 1996; 36: 3595–3600. https://doi.org/10.1128/JCM.36.12.3595-3600.1996 PMID: 9817879

28. Chakraborthy S, Alam M, Scobie HM, Sack DA. Adaptation of a simple dipstick test for detection of Vibrio cholerae O1 and O139 in environmental water. Front Microbiol. 2013; 4: 320–320. https://doi.org/10.3389/fmicb.2013.00320 PMID: 24194737

29. Colwell RR, Hasan JAK, Huq A, Loomis L, Siebeling RJ, Torres M, et al. Development and evaluation of a rapid, simple, sensitive, monoclonal antibody-based co-agglutination test for direct detection of Vibrio cholerae O1. FEMS Microbiol Lett. 1992; 97: 215–219. https://doi.org/10.1016/0378-1097(92)90339-p PMID: 1427010

30. Debes AK, Atiedjie J, Guenou E, Ebile W, Sonkoua IT, Njimbia AC, et al. Clinical and environmental surveillance for vibrio cholerae in resource constrained areas: Application during a 1-year surveillance in the Far North Region of Cameroon. Am J Trop Med Hyg. 2016; 94: 856–857.1994 PMID: 8195409

31. Eddabra R, Piemont Y, Schelft JM. Evaluation of a new chromogenic medium, chromID™ Vibrio, for the isolation and presumptive identification of Vibrio cholerae and Vibrio parahaemolyticus from human clinical specimens. Eur J Clin Microbiol Infect Dis. 2011; 30: 733–737. https://doi.org/10.1007/s10096-010-1145-2 PMID: 21494255

32. George CM, Rashid M-U, Sack DA, Bradley Sack R, Sall-Uri-Rahman KM, Azman AS, et al. Evaluation of enrichment method for the detection of Vibrio cholerae O1 using a rapid dipstick test in Bangladesh. Trop Med Int Health. 2011; 14: 301–307. https://doi.org/10.1111/j.1365-3156.2011.05880.x PMID: 21400113

33. Hao M, Zhang P, Li B, Liu X, Zhao Y, Tan H, et al. Development and evaluation of an upconverting phosphor technology-based lateral flow assay for the rapid, simultaneous detection of Vibrio cholerae serogroups O1 and O139. PLoS ONE. 2017; 12. https://doi.org/10.1371/journal.pone.0179937 PMID: 28662147
34. Harris JR, Cavallaro EC, De Nóbrega AA, Dos S. Barrado JCB, Bopp C, Parsons MB, et al. Field evaluation of crystal VC™ rapid dipstick test for cholera during a cholera outbreak in Guinea-Bissau. Trop Med Int Health. 2009; 14: 1117–1121. https://doi.org/10.1111/j.1365-3156.2009.02335.x PMID: 19624473

35. Hasan JAK, Bernstein D, Huq A, Loomis L, Tamplin ML, Colwell RR. Cholera DFA: An improved direct fluorescent monoclonal antibody staining kit for rapid detection and enumeration of Vibrio cholerae O1. FEBS Microbiol Lett. 1994; 120: 143–148. https://doi.org/10.1111/j.1574-6968.1994.tb07021.x PMID: 8056287

36. Hasan JAK, Huq A, Tamplin ML, Siebeling RJ, Colwell RR. A novel kit for rapid detection of Vibrio cholerae O1. J Clin Microbiol. 1994; 32: 249–252. https://doi.org/10.1128/jcm.32.1.249-252.1994 PMID: 8126193

37. Hasan JAK, Huq A, Nair GB, Garg S, Mukhopadhay AK, Loomis L, et al. Development and testing of monoclonal antibody-based rapid immunodiagnostic test kits for direct detection of Vibrio cholerae O139 synonym Bengal. J Clin Microbiol. 1995; 33: 2935–2939. https://doi.org/10.1128/jcm.33.11.2935-2939.1995 PMID: 8576349

38. Hoshino K, Yamasaki S, Mukhopadhay AK, Chakraborty S, Basu A, Bhattacharya SK, et al. Development and evaluation of a multiplex PCR assay for rapid detection of toxigenic Vibrio cholerae O1 and O139. FEMS Immunol Med Microbiol. 1998; 20: 201–207. https://doi.org/10.1111/j.1574-696X.1998.tb01128.x PMID: 9566491

39. Islam MS, Hasan MK, Miah MA, Huq A, Bardhan PK, Sack RB, et al. Specificity of Cholera Screen™ test during an epidemic of cholera-like disease due to Vibrio cholerae O139 synonym Bengal. Trans R Soc Trop Med Hyg. 1994; 88: 424–425. https://doi.org/10.1016/0035-9203(94)90413-8 PMID: 7570828

40. Islam T, Khan Ashraful Islam, Sayeed A, Amin J, Islam K, Alam N, et al. Field evaluation of a locally produced rapid diagnostic test for early detection of cholera in Bangladesh. PLoS Negl Trop Dis. 2019; 13. https://doi.org/10.1371/journal.pntd.0007124 PMID: 30703097

41. Jin D, Luo Y, Zheng M, Li H, Zhang J, Stampfl M, et al. Quantitative detection of vibrio cholera toxin by real-time and dynamic cytotoxicity monitoring. J Clin Microbiol. 2013; 51: 3968–3974. https://doi.org/10.1128/jcm.01959-13 PMID: 24048535

42. Kalluri P, Naheed A, Rahman S, Ansaruzzaman M, Faruque ASG, Bird M, et al. Evaluation of three rapid diagnostic tests for cholera: Does the skill level of the technician matter? Trop Med Int Health. 2006; 11: 49–55. https://doi.org/10.1111/j.1365-3156.2005.01539.x PMID: 16398775

43. Ley B, Khatib AM, Thriemer K, von Seidlein L, Deen J, Mukhopadyay A, et al. Evaluation of a rapid diagnostic test (crystal VC) for the diagnosis of Cholera in Zanzibar and a comparison with previous studies. PLoS ONE. 2012; 7. https://doi.org/10.1371/journal.pone.0036930 PMID: 22662131

44. Liu J, Gratz J, Amour C, Kibiki G, Becker S, Janaki L, et al. A laboratory-developed tagman array card for simultaneous detection of 19 enteropathogens. J Clin Microbiol. 2013; 51: 472–480. https://doi.org/10.1128/JCM.02658-12 PMID: 23175269

45. Matias WR, Juleceus FE, Abelard C, Mayo-Smith LM, Franke MF, Harris JB, et al. Laboratory evaluation of immunochromatographic rapid diagnostic tests for cholera in Haiti. PLOS ONE. 2017; 12: e0186710. https://doi.org/10.1371/journal.pone.0186710 PMID: 29056287

46. Momtaz H, Dehkordi FS, Rahimi E, Asgari far A. Detection of Escherichia coli, Salmonella species, and Vibrio cholerae in tap water and bottled drinking water in Isfahan, Iran. BMC Public Health. 2013; 13. https://doi.org/10.1186/1471-2458-13-556 PMID: 23742181

47. Mukherjee P, Ghosh S, Ramamurthy MK, Nandy RK, Takeda Y, et al. Evaluation of a rapid immunochromatographic dipstick kit for diagnosis of cholera emphasizes its outbreak utility. Jpn J Infect Dis. 2010; 63: 234–238. PMID: 19626193

48. Mwaba J, Ferreras E, Chizema-Kawesa Elizabeth, Mwimbe D, Tafirenyi KA, Rauzier J, et al. Evaluation of the SD bioline cholera rapid diagnostic test during the 2016 cholera outbreak in Lusaka, Zambia. Trop Med Int Health. 2018; 23: 834–840. https://doi.org/10.1111/tmi.13084 PMID: 29851181

49. Nato F, Boutonnier A, Rajerison M, Grosjean P, Darceville S, Guénoël A, et al. One-step immunochromatographic dipstick tests for rapid detection of Vibrio cholerae O1 and O139 in stool samples. Clin Diagn Lab Immunol. 2003; 10: 476–478. https://doi.org/10.1128/cdli.10.3.476-478.2003 PMID: 12738652

50. Page A-L, Alberti KP, Mondonge V, Rauzier J, Quilici M-L, Guerin PJ. Evaluation of a rapid test for the diagnosis of cholera in the absence of a gold standard. PLoS ONE. 2012; 7. https://doi.org/10.1371/journal.pone.0037360 PMID: 2266350

51. Qadri F, Chowdhury A, Hossain J, Chowdhury K, Azim T, Shimada T, et al. Development and evaluation of rapid monoclonal antibody-based coagglutination test for direct detection of Vibrio cholerae O139 synonym Bengal in stool samples. J Clin Microbiol. 1994; 32: 1589–1590. https://doi.org/10.1128/jcm.32.6.1589-1590.1994 PMID: 8077410
52. Qadri F, Hasan JAK, Hossain A, Chowdhury A, Ara Begum Y, Azim T, et al. Evaluation of the monoclonal antibody-based kit Bengal SMART for rapid detection of Vibrio cholerae O139 synonym Bengal in stool samples. J Clin Microbiol. 1995; 33: 732–734. https://doi.org/10.1128/jcm.33.3.732-734.1995 PMID: 7751386

53. Ramamurthy T, Bhattacharya SK, Uesaka Y, Horigome K, Paul M, Sen D, et al. Evaluation of the bead enzyme-linked immunosorbent assay for detection of cholera toxin directly from stool specimens. J Clin Microbiol. 1992; 30: 1783–1786. https://doi.org/10.1128/jcm.30.7.1783-1786.1992 PMID: 1629335

54. Ramamurthy T, Pal A, Bag PK, Bhattacharya SK, Nair GB, Kurozono H, et al. Detection of cholera toxin gene in stool specimens by polymerase chain reaction: Comparison with bead enzyme-linked immunosorbent assay and culture method for laboratory diagnosis of cholera. J Clin Microbiol. 1993; 31: 3068–3070. https://doi.org/10.1128/jcm.31.11.3068-3070.1993 PMID: 8263204

55. Ramamurthy T, Bhattacharya SK, Nair GB, Takeda Y. Comparison of the sensitivity & specificity of a polyclonal versus monoclonal capture antibody based Bead ELISA for direct detection of cholera toxin from stool specimens. Indian J Med Res. 1996; 104: 125–128. PMID: 8783514

56. Sayeed MA, Islam K, Hossain M, Akter NJ, Alam MN, Sultana N, et al. Development of a new dipstick (Cholkit) for rapid detection of Vibrio cholerae O1 in acute watery diarrheal stools. PLoS Negl Trop Dis. 2018; 12. https://doi.org/10.1371/journal.pntd.0006286 PMID: 29538377

57. Supawat K., Huttayanonont S., Kusum M., Kalambaheti T., Chaicumpa W. A monoclonal antibody-based dot-blot ELISA diagnostic kit for the detection of Vibrio cholerae O1 in stools of diarrheic patients and household contacts. Asian Pac J Allergy Immunol. 1994; 12: 155–159. PMID: 7612110

58. Tuteja U, Kumar S, Shukla J, Kingston J, Batra HV. Simultaneous direct detection of toxigenic and non-toxigenic Vibrio cholerae from rectal swabs and environmental samples by sandwich ELISA. J Med Microbiol. 2007; 56: 1340–1345. https://doi.org/10.1099/jmm.0.47166-0 PMID: 17893171

59. Wang X-Y, Ansaruzzaman M, Vaz R, Mondlane C, Lucas MES, von Seidlein L, et al. Field evaluation of a rapid immunochromatographic dipstick test for the diagnosis of cholera in a high-risk population. BMC Infect Dis. 2006; 6. https://doi.org/10.1186/1471-2334-6-17 PMID: 16451731

60. Lee J, Kim KW, Choi SH, Huh J, Park SH. Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers-Part II. Statistical Methods of Meta-Analysis. Korean J Radiol. 2015; 16: 1188–1196. https://doi.org/10.3348/kjr.2015.16.6.1188 PMID: 26576107

61. Jones CM, Athanasiou T. Summary Receiver Operating Characteristic Curve Analysis Techniques in the Evaluation of Diagnostic Tests. Ann Thorac Surg. 2005; 79: 16–20. https://doi.org/10.1016/j.athoracsur.2004.09.040 PMID: 15629907

62. Bossuyt PM, Rieksma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015; 351: h5527. https://doi.org/10.1136/bmj.h5527 PMID: 26511519

63. Ndlovu Z, Masaquoi L, Bangwen NE, Batumba JN, Bora RU, Mbuaya J, et al. Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening. PloS One. 2020; 15: e0230453. https://doi.org/10.1371/journal.pone.0230453 PMID: 32243435

64. Uwamino Y, Wakui M, Aoki W, Kurafuli T, Yanagita E, Morita M, et al. Evaluation of the usability of various rapid antibody tests in the diagnostic application for COVID-19. Ann Clin Biochem. 2021; 58: 174–180. https://doi.org/10.1177/0004563220984927 PMID: 33334135